NEW YORK (GenomeWeb News) - Agencourt Bioscience will provide genomic sequencing services to the National Cancer Institute under a one-year agreement with an option to renew for a second year, the company said today.
Under the contract, Agencourt, a subsidiary of Beckman Coulter, will perform genomic sequencing on normal and cancer tissue samples and on genes and targeted regions for NCI and for its collaborators.
These NCI collaborators, “may request the sequencing of specific genes at any time,” Agencourt said.
Collaborators will submit sequence trace data to the National Center for Biotechnology information, and base calls will be placed in a database managed by the NCI, Agencourt said.
The company plans to develop a website that will be accessible to project collaborators and allow them to query the NCBI Trace database for additional metadata and relate it to other experimental results and clinical data.
Financial terms of the agreement were not released.